News & Updates

Show Multimedia Only
Avacincaptad pegol slows geographic atrophy progression
Avacincaptad pegol slows geographic atrophy progression
27 Mar 2026 byStephen Padilla

Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.

Avacincaptad pegol slows geographic atrophy progression
27 Mar 2026
CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
27 Mar 2026